Clinical Validity and Utility of Multi-Omic Risk Scores in Type 2 Diabetes: Implications for Population Screening and Policy

Ivan Mutebi

Department of Pharmacognosy Kampala International University Uganda

Email: ivan.mutebi@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes (T2D) represents a growing global health challenge, with early detection of at-risk individuals being critical for prevention and management. Traditional risk factors and biomarkers, while informative, have limited predictive accuracy, particularly for younger populations. Multi-omic risk scores integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic data offer a promising avenue for refined risk prediction. Evidence to date indicates moderate analytical and clinical validity, with incremental predictive value over conventional risk factors demonstrated in large population-based cohorts such as Whitehall II and LifeLines. Challenges remain regarding standardization, cross-platform integration, population transferability, and implementation at scale. Ethical, legal, and social considerations, as well as cost-effectiveness, must guide deployment. Integration with electronic health systems and ongoing pilot studies are essential to establish population-level clinical utility and to inform public health policy for targeted T2D prevention.

Keywords: Type 2 diabetes, Multi-omic risk scores, Population screening, Clinical utility, and Precision prevention.

CITE AS: Ivan Mutebi (2026). Clinical Validity and Utility of Multi-Omic Risk Scores in Type 2 Diabetes: Implications for Population Screening and Policy. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 6(1):68-76. https://doi.org/10.59298/RIJBAS/2026/616876